Kctd12b inhibitors represent a class of chemical compounds designed to target and interfere with the activity of the Kctd12b gene or its encoded protein product. Kctd12b, or Potassium Channel Tetramerization Domain-Containing 12B, is a gene or protein that may have diverse functions in cellular processes. These inhibitors are developed with the aim of modulating the function of Kctd12b, which could participate in various biological processes, such as ion channel regulation, protein-protein interactions, or other molecular activities within cells.
The primary mechanism of action for Kctd12b inhibitors typically involves their interaction with the Kctd12b protein or its associated molecules, resulting in the disruption of its normal function. By inhibiting Kctd12b, these compounds may impact cellular processes under its control, although the specific functions of Kctd12b are still being explored by researchers. Scientists studying Kctd12b inhibitors aim to elucidate the precise roles and functions of Kctd12b in cellular biology, contributing to our understanding of its significance within cellular processes. These inhibitors serve as valuable tools for advancing our knowledge of less-characterized genes or proteins, enabling the exploration of new areas of molecular and cellular biology research. In this context, they contribute to expanding our understanding of the intricate world of cellular functions and molecular interactions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Sirolimus can inhibit mTOR, which may downregulate the expression of certain genes as part of complex intracellular signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, potentially affecting gene expression downstream of PI3K/Akt signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, which could alter gene expression profiles linked to inflammation and stress responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, modulating gene expression related to apoptosis and other cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK, which may result in changes to gene expression through the MAPK/ERK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor that could affect the transcription of genes regulated by the PI3K/Akt pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK, which may influence gene transcription through the MAPK/ERK signaling pathway. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
C646 is a selective p300/CBP histone acetyltransferase inhibitor that may alter chromatin structure and gene expression. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $182.00 $661.00 | 10 | |
Chetomin disrupts the interaction between HIF-1α and p300/CBP, which might affect gene transcription under hypoxic conditions. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 inhibits the proteasome, potentially affecting protein degradation and gene expression indirectly. | ||||||